Leukocyte Surface Antigen CD47 Antibody Market size was valued at USD 0.45 Billion in 2022 and is projected to reach USD 1.2 Billion by 2030, growing at a CAGR of 14.2% from 2024 to 2030.
The Leukocyte Surface Antigen CD47 Antibody market is experiencing robust growth as this area of immunology continues to evolve, driven by the increasing research in oncology, immunology, and autoimmune diseases. CD47, a cell surface protein, has gained significant attention due to its role in immune regulation and its potential as a therapeutic target. The antibodies targeting CD47 are essential tools in research and diagnostics. These antibodies are widely used in various laboratory applications, including flow cytometry, enzyme-linked immunosorbent assay (ELISA), western blotting, immunoprecipitation, and immunofluorescence, among others. Each of these applications plays a critical role in advancing the understanding of CD47’s functions and its implications in various diseases, such as cancer and cardiovascular conditions.
Download Full PDF Sample Copy of Leukocyte Surface Antigen CD47 Antibody Market Report @ https://www.verifiedmarketreports.com/download-sample/?rid=455080&utm_source=GSJ&utm_medium=204
Flow cytometry is one of the most widely used techniques for analyzing the expression of cell surface markers, including CD47, and assessing cell behavior in response to different stimuli. This method involves the use of fluorescently labeled antibodies, such as those targeting CD47, which are passed through a laser to measure various characteristics of individual cells. By detecting the light scatter and fluorescence emitted by the antibody-tagged cells, flow cytometry provides detailed quantitative data on the presence and quantity of CD47 expression on cell surfaces. It is commonly applied in research to explore immune system functions, identify cancer cells, and understand how CD47 contributes to immune evasion by cancer cells. The key advantage of using CD47 antibodies in flow cytometry is their ability to detect cell-surface antigens with high specificity and sensitivity. This application is particularly useful for analyzing heterogeneous cell populations, such as those found in blood or tumor microenvironments, and can provide insights into how CD47 interacts with various immune cells like macrophages and T-cells. The ability to isolate specific populations and analyze their behavior in real-time under various conditions makes flow cytometry indispensable in CD47 research, especially in cancer immunotherapy and drug development.
ELISA is a commonly used assay to quantify and detect antibodies or antigens in a sample. In the case of CD47 antibodies, ELISA is employed to measure the concentration of CD47 on cell surfaces or in serum samples. The test involves coating a plate with the antigen or antibody, followed by the addition of a sample containing the target CD47 antigen or antibody. The interaction is then detected using an enzyme-linked secondary antibody that generates a colorimetric change, which can be quantified using spectrophotometry. ELISA is particularly useful for the detection of soluble CD47 levels in biological fluids, offering a non-invasive method for monitoring changes in CD47 expression associated with various disease states. ELISA-based assays targeting CD47 are often used in both research and diagnostic settings to assess immune responses and disease progression. The application of CD47 antibodies in ELISA is essential in understanding how the protein functions in both normal and disease conditions, particularly in the context of cancer immunotherapy. It provides a high-throughput, cost-effective approach to analyze CD47 expression across various patient samples, which can be crucial for biomarker discovery and the evaluation of therapeutic interventions. Additionally, ELISA is scalable, making it suitable for large-scale studies involving multiple patient cohorts or animal models.
Western blotting is a highly sensitive technique used to detect specific proteins, including CD47, within complex protein mixtures. This technique involves the separation of proteins by gel electrophoresis, followed by transfer to a membrane where antibodies are used to specifically bind to the target protein. In the case of CD47, primary antibodies are applied to the membrane, and secondary antibodies conjugated to a detection enzyme or fluorophore allow for the visualization of the target protein. Western blotting is especially useful for confirming the molecular weight and expression levels of CD47 in various cell types, tissues, or biological fluids. The application of CD47 antibodies in western blotting plays a critical role in validating research findings related to the molecular characterization of CD47 and its signaling pathways. This technique is frequently used in both basic research and clinical applications to provide a detailed understanding of CD47 expression and its potential as a therapeutic target. Western blotting can detect altered expression levels of CD47 in disease states, particularly cancer, where overexpression or altered trafficking of CD47 has been linked to immune evasion mechanisms. Its high sensitivity allows researchers to detect even low levels of CD47 expression in various samples, making it an essential tool in biomarker discovery.
Immunoprecipitation (IP) is a technique used to isolate and purify specific proteins or protein complexes from a mixture using antibodies. In the context of CD47, IP can be used to capture CD47-bound proteins, offering a way to study its interactions with other proteins involved in immune responses, signal transduction, and disease processes. CD47 antibodies are employed to bind to CD47 on the cell surface, allowing researchers to pull down CD47 or its associated signaling molecules from complex mixtures. The captured protein complexes can then be analyzed by various downstream techniques, such as mass spectrometry or western blotting, to identify interacting proteins or assess changes in protein expression. Immunoprecipitation using CD47 antibodies is a valuable tool in functional proteomics and interaction studies, particularly for understanding how CD47 influences immune cell signaling and modulates the immune response. For instance, CD47 has been implicated in cancer immunoevasion through its interaction with the macrophage receptor SIRPα, and IP assays can help elucidate the dynamics of this interaction. By isolating and studying the associated protein complexes, researchers gain insights into how CD47 mediates immune cell inhibition and its potential as a therapeutic target for cancer and autoimmune diseases.
Immunofluorescence (IF) is a powerful imaging technique used to visualize the localization of specific antigens, such as CD47, within tissues or cells. This technique involves using antibodies conjugated to fluorescent dyes to bind to the target antigen. When exposed to a specific wavelength of light, these fluorescent markers emit light at different wavelengths, allowing the visualization of the antigen under a fluorescence microscope. In the case of CD47, immunofluorescence is frequently used to study the spatial distribution of CD47 expression on cell surfaces, its internalization in immune cells, and its co-localization with other cell surface markers. The use of CD47 antibodies in immunofluorescence is crucial for understanding the role of CD47 in various biological processes, including immune regulation, tumor progression, and tissue development. By providing detailed, high-resolution images of CD47 distribution in different cell types and tissues, immunofluorescence enables researchers to investigate how CD47 interacts with other molecules in its native cellular environment. This application is especially important for visualizing the dynamic changes in CD47 expression in response to immune system activation or during the course of diseases such as cancer, providing valuable insights into potential therapeutic strategies.
The Leukocyte Surface Antigen CD47 antibody market is expected to witness continued growth, driven by the increasing emphasis on immunotherapies for cancer and autoimmune diseases. One key trend is the rising demand for CD47-targeted therapies, particularly in the context of cancer immunotherapy. CD47 has been identified as a critical immune checkpoint that cancer cells exploit to evade immune detection, making it a prime target for monoclonal antibody-based therapies. The increasing investment in clinical trials focused on CD47 blockade or CD47-SIRPα pathway modulation is fueling the demand for high-quality CD47 antibodies. This trend is being further supported by advancements in biotechnology and antibody engineering technologies, which are improving the specificity, efficacy, and safety of CD47-targeted therapies. Another important trend is the growing integration of CD47 antibody-based diagnostics in clinical practice. With the increasing recognition of CD47 as a biomarker for various diseases, particularly cancer, diagnostic tests that utilize CD47 antibodies are becoming more prevalent. These tests allow for early detection and monitoring of disease progression, particularly in oncology. Furthermore, as the understanding of CD47's role in immune modulation expands, new applications are emerging, such as CD47-based immunoassays for monitoring autoimmune diseases and transplant rejection. The continued evolution of antibody-based technologies and their applications is expected to shape the future of the CD47 antibody market significantly.
The Leukocyte Surface Antigen CD47 antibody market presents numerous opportunities, particularly in the development of novel therapeutic antibodies. The discovery of CD47’s role in immune evasion has opened new avenues for cancer treatment, and the growing interest in CD47 blockade therapies represents a major opportunity for biotechnology and pharmaceutical companies. Developing monoclonal antibodies that can effectively inhibit the CD47-SIRPα interaction has the potential to revolutionize cancer immunotherapy, particularly in hematologic cancers like leukemia and lymphoma, where CD47 expression is often elevated. Additionally, CD47-targeted therapies offer a promising complement to existing treatments like checkpoint inhibitors and CAR-T cell therapies. In the diagnostics sector, the increasing use of CD47 antibodies for biomarker identification and disease monitoring presents a significant opportunity for diagnostic companies. As CD47 becomes a key biomarker for various types of cancer and autoimmune diseases, there is potential for the development of companion diagnostics that can guide treatment decisions. Moreover, the application of CD47 antibodies in early detection and prognosis could improve patient outcomes, creating substantial growth opportunities for companies involved in diagnostic assays and biomarker research. The market is also poised for growth with the introduction of innovative technologies that enhance the sensitivity and accuracy of CD47 detection
Top Leukocyte Surface Antigen CD47 Antibody Market Companies
Sino Biological
Inc.
Cell Signaling Technology
Inc.
Bio-Techne
OriGene Technologies
Inc.
LifeSpan BioSciences
Inc
Abbexa
MyBiosource
Inc.
Biorbyt
Creative Biolabs
GeneTex
Arigo Biolaboratories Corp.
​​Abcam
RayBiotech
Inc.
Assay Genie
Regional Analysis of Leukocyte Surface Antigen CD47 Antibody Market
North America (United States, Canada, and Mexico, etc.)
Asia-Pacific (China, India, Japan, South Korea, and Australia, etc.)
Europe (Germany, United Kingdom, France, Italy, and Spain, etc.)
Latin America (Brazil, Argentina, and Colombia, etc.)
Middle East & Africa (Saudi Arabia, UAE, South Africa, and Egypt, etc.)
For More Information or Query, Visit @
Leukocyte Surface Antigen CD47 Antibody Market Insights Size And Forecast